Li et al. identified a correlation between ROS1 gene alterations and increased TMB levels through analyzing an immunotherapy database, a finding that aligns with our observations, suggesting that ROS1 may serve as a favorable prognostic biomarker for various cancer patients undergoing ICIs treatment (Li et al., 2020). This evidence concerns the gene ROS1 and cancer.